Michael R. Sisak
The Associated Press
New York, NY, United States
Contact Michael
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Recent articles by Michael:
'Pharma Bro' Shkreli ordered to return $64M, is barred from drug industry
NEW YORK (AP) - A federal judge on Friday ordered Martin Shkreli to return $64. 6 million in profits he and his company reaped from inflating the price of the life-saving drug Daraprim and barred him from participating in the pharmaceutical industry for the rest of his life. The ruling by U. S. District Judge Denise Cote came several weeks after a seven-day bench trial in December. → Read More
Martin Shkreli ordered to return $64 million in pharmaceutical drug profits
Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More
Martin Shkreli ordered to return $64 million in pharmaceutical drug profits
Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More
Martin Shkreli ordered to return $64 million in pharmaceutical drug profits
Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More
Martin Shkreli ordered to return $64 million in pharmaceutical drug profits
Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More
Martin Shkreli ordered to return $64 million in pharmaceutical drug profits
Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More
Martin Shkreli ordered to return $64 million in pharmaceutical drug profits
Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More
Martin Shkreli ordered to return $64 million in pharmaceutical drug profits
Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More
Martin Shkreli ordered to return $64 million in pharmaceutical drug profits
Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More
Martin Shkreli ordered to return $64 million in pharmaceutical drug profits
Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More
Martin Shkreli ordered to return $64 million in pharmaceutical drug profits
Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More
Martin Shkreli ordered to return $64 million in pharmaceutical drug profits
Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More
Martin Shkreli ordered to return $64 million in pharmaceutical drug profits
Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More
Martin Shkreli ordered to return $64 million in pharmaceutical drug profits
Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More
Martin Shkreli ordered to return $64 million in pharmaceutical drug profits
Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More
Martin Shkreli ordered to return $64 million in pharmaceutical drug profits
Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More
Martin Shkreli ordered to return $64 million in pharmaceutical drug profits
Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More
Martin Shkreli ordered to return $64 million in pharmaceutical drug profits
Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More
Martin Shkreli ordered to return $64 million in pharmaceutical drug profits
Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More
Martin Shkreli ordered to return $64 million in pharmaceutical drug profits
Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it raised the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. → Read More